Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer

Letter/Communication

Open access

Ashish M Kamat, Seth Lerner, Peter Black, Joaquim Bellmunt, Colin Dinney, Noah M Hahn, Michael O’Donnell and Diane Z Quale

Bladder cancer, Vol.3(3), pp.145-146

07/27/2017

DOI: 10.3233/BLC-170118

PMCID: PMC5545902

PMID: 28824940

Files and links (1)

url

https://doi.org/10.3233/BLC-170118View

Published (Version of record) Open Access

Title: Subtitle: Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
Creators: Ashish M Kamat - Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Seth Lerner - Department of Urologic Oncology, Baylor College of Medicine, TCGA Bladder Cancer, Houston, TX, USA
Peter Black - University of British Columbia, Vancouver, BC, Canada
Joaquim Bellmunt - Department of Medicine, Harvard Medical School, Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA
Colin Dinney - Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Noah M Hahn - Department of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Michael O’Donnell - Departments of Urology and Urologic Oncology, The University of Iowa, Iowa City, Iowa, IA, USA
Diane Z Quale - BCAN (Bladder Cancer Advocacy Network), Baltimore, MD, USA
Resource Type: Letter/Communication
Publication Details: Bladder cancer, Vol.3(3), pp.145-146
DOI: 10.3233/BLC-170118
PMID: 28824940
PMCID: PMC5545902
NLM abbreviation: Bladder Cancer
ISSN: 2352-3727
eISSN: 2352-3727
Language: English
Date published: 07/27/2017
Academic Unit: Urology
Record Identifier: 9984051505902771

91 Record Views